AstraZeneca's triple whammy of good news pleases market

AstraZeneca pleased the market with a triple dose of good news yesterday as it won endorsement in the United States for its new blood-thinning drug Brilinta, reported strong results and doubled its share buyback programme.

The Anglo-Swedish group is expecting annual sales of more than $1bn (£640m) from Brilinta. Its prospects were boosted yesterday when the US Food and Drug Administration (FDA) advisory panel gave initial backing for the treatment.

It voted 7-1 in favour of approving the treatment, despite some unfavourable trial data, and Brilinta being tested on a relatively low number of patients in the US.

Details of the FDA vote came as AstraZeneca reported a better-than-expected 5 per cent increase in core profits in the second quarter, to $3.53bn. The performance was helped by generic competitors being slow to copy a number of off-patent drugs, including the blockbuster ulcer treatment, Nexium.

AstraZeneca's chief executive officer, David Brennan, said: "Our second-quarter performance reflects continued strong growth in our emerging markets and good performance for key brands Crestor, Seroquel and Symbicort."

The second-quarter results led the group to double the size of its $1bn share-buyback programme, which was announced in January to "[recognise] that some earnings fluctuations are to be expected as the company's revenue base transitions through this period of exclusivity losses and new product launches." The positive updates pushed the group's shares up by 86.5p to 3,289p.

Despite the results, and the comments from the FDA, a number of industry analysts were cautious on AstraZeneca's longer-term prospects. The results were "the last pre-key-patent-expiry set of results for AstraZeneca, with Brilinta's recommendation the last of the significant expected positive newsflow," said Collins Stewart's analyst, Emmanuel Papadakis.

The group is the UK's second-biggest drug-maker behind GlaxoSmithKline and acknowledges that it has been slow at bringing new drugs to development, a problem exacerbated by its ageing portfolio of current medicines.

"We haven't been as productive as we would have liked to have been in the last few years and for a pharmaceutical company, that's pretty significant, right?" Mr Brennan said in a recent interview with The Independent.

"I would like to see sustainable delivery on a consistent basis from our research and development organisation, and that's why they have been set a goal: from the beginning in 2010, on average, we will bring two new products to the market each year. That's our goal and that's what I want to be measured against," he added.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Financial Controller

£45 - £55k DOE: Guru Careers: A Financial Controller is required to join a suc...

Recruitment Genius: Sales Consultant / Telemarketer - OTE £20,000

£12500 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...

Recruitment Genius: Sales Adviser - OTE £24,500

£22500 - £24500 per annum: Recruitment Genius: Inbound and outbound calls with...

Recruitment Genius: Business Development Executive / Sales - OTE £40,000

£18000 - £40000 per annum: Recruitment Genius: This fast growing Insurance Bro...

Day In a Page

Mullah Omar, creator of the Taliban, is dead... for the fourth time

Mullah Omar, creator of the Taliban, is dead... again

I was once told that intelligence services declare their enemies dead to provoke them into popping up their heads and revealing their location, says Robert Fisk
Margaret Attwood on climate change: 'Time is running out for our fragile, Goldilocks planet'

Margaret Attwood on climate change

The author looks back on what she wrote about oil in 2009, and reflects on how the conversation has changed in a mere six years
New Dr Seuss manuscript discovered: What Pet Should I Get? goes on sale this week

New Dr Seuss manuscript discovered

What Pet Should I Get? goes on sale this week
Oculus Rift and the lonely cartoon hedgehog who could become the first ever virtual reality movie star

The cartoon hedgehog leading the way into a whole new reality

Virtual reality is the 'next chapter' of entertainment. Tim Walker gives it a try
Ants have unique ability to switch between individual and collective action, says study

Secrets of ants' teamwork revealed

The insects have an almost unique ability to switch between individual and collective action
Donovan interview: The singer is releasing a greatest hits album to mark his 50th year in folk

Donovan marks his 50th year in folk

The singer tells Nick Duerden about receiving death threats, why the world is 'mentally ill', and how he can write a song about anything, from ecology to crumpets
Let's Race simulator: Ultra-realistic technology recreates thrill of the Formula One circuit

Simulator recreates thrill of F1 circuit

Rory Buckeridge gets behind the wheel and explains how it works
Twitter accused of 'Facebookisation' over plans to overhaul reverse-chronological timeline

Twitter accused of 'Facebookisation'

Facebook exasperates its users by deciding which posts they can and can’t see. So why has Twitter announced plans to do the same?
Jane Birkin asks Hermès to rename bag - but what else could the fashion house call it?

Jane Birkin asks Hermès to rename bag

The star was shocked by a Peta investigation into the exotic skins trade
10 best waterproof mascaras

Whatever the weather: 10 best waterproof mascaras

We found lash-enhancing beauties that won’t budge no matter what you throw at them
Diego Costa biography: Chelsea striker's route to the top - from those who shared his journey

Diego Costa: I go to war. You come with me...

Chelsea's rampaging striker had to fight his way from a poor city in Brazil to life at the top of the Premier League. A new book speaks to those who shared his journey
Ashes 2015: England show the mettle to strike back hard in third Test

England show the mettle to strike back hard in third Test

The biggest problem facing them in Birmingham was the recovery of the zeitgeist that drained so quickly under the weight of Australian runs at Lord's, says Kevin Garside
Women's Open 2015: Charley Hull - 'I know I'm a good golfer but I'm also just a person'

Charley Hull: 'I know I'm a good golfer but I'm also just a person'

British teen keeps her feet on ground ahead of Women's Open
Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

Turkish President Erdogan could benefit politically from the targeting of the PKK, says Patrick Cockburn
Yvette Cooper: Our choice is years of Tory rule under Jeremy Corbyn or a return to a Labour government

Our choice is years of Tory rule under Corbyn or a return to a Labour government

Yvette Cooper urged Labour members to 'get serious' about the next general election rather than become 'a protest movement'